Glabrescione B

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

glabrescione B: a Hedgehog pathway inhibitor; isolated from Derris glabrescens; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	44257338
CHEMBL ID	4291780
CHEBI ID	186122
SCHEMBL ID	16335460

Synonyms (15)

Synonym
LMPK12050359
5,7-dimethoxy-3',4'-diprenyloxyisoflavone
glabrescione b
CHEBI:186122
3-[3,4-bis(3-methylbut-2-enoxy)phenyl]-5,7-dimethoxychromen-4-one
SCHEMBL16335460
HY-122590
CS-0087327
65893-94-9
3-[3,4-bis-(3-methyl-but-2-enyloxy)-phenyl]-5,7-dimethoxy-chromen-4-one;glabrescine b;glabrescion b
A901959
MS-28173
CHEMBL4291780
AKOS040758261
3-[3,4-bis-(3-methyl-but-2-enyloxy)-phenyl]-5,7-dimethoxy-chromen-4-one

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

Class	Description
methoxyisoflavone	Members of the class of isoflavones with at least one methoxy substituent.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (16)

Assay ID	Title	Year	Journal	Article
AID1655599	Inhibition of GLI1 transcriptional activity in human A375 cells assessed as downregulation of GLI2 mRNA expression at 5 uM incubated for 48 hrs by qPCR analysis	2020	ACS medicinal chemistry letters, May-14, Volume: 11, Issue:5	Pharmacophore-Based Virtual Screening for Identification of Negative Modulators of GLI1 as Potential Anticancer Agents.
AID1655600	Inhibition of GLI1 transcriptional activity in human A375 cells assessed as downregulation of Cyclin D1 mRNA expression at 5 uM incubated for 48 hrs by qPCR analysis	2020	ACS medicinal chemistry letters, May-14, Volume: 11, Issue:5	Pharmacophore-Based Virtual Screening for Identification of Negative Modulators of GLI1 as Potential Anticancer Agents.
AID1655593	Antiproliferative activity against human DaOY cells assessed as reduction in cell viability incubated for 72 hrs by trypan blue or crystal violet staining based assay	2020	ACS medicinal chemistry letters, May-14, Volume: 11, Issue:5	Pharmacophore-Based Virtual Screening for Identification of Negative Modulators of GLI1 as Potential Anticancer Agents.
AID1655598	Inhibition of GLI1 transcriptional activity in human A375 cells assessed as downregulation of HIP1 mRNA expression at 5 uM incubated for 48 hrs by qPCR analysis	2020	ACS medicinal chemistry letters, May-14, Volume: 11, Issue:5	Pharmacophore-Based Virtual Screening for Identification of Negative Modulators of GLI1 as Potential Anticancer Agents.
AID1655595	Inhibition of GLI1 transcriptional activity in HH-responsive mouse NIH3T3 cells assessed as reduction in SAG-induced luciferase activity at 5 uM incubated for 48 hrs by luciferase reporter gene assay relative to control	2020	ACS medicinal chemistry letters, May-14, Volume: 11, Issue:5	Pharmacophore-Based Virtual Screening for Identification of Negative Modulators of GLI1 as Potential Anticancer Agents.
AID1406172	Growth inhibition of mouse Ptch+/- medulloblastoma cells at 0.5 uM after 72 hrs relative to control	2018	European journal of medicinal chemistry, Aug-05, Volume: 156	Synergistic inhibition of the Hedgehog pathway by newly designed Smo and Gli antagonists bearing the isoflavone scaffold.
AID1655597	Inhibition of GLI1 transcriptional activity in human A375 cells assessed as downregulation of PTCH1 mRNA expression at 5 uM incubated for 48 hrs by qPCR analysis	2020	ACS medicinal chemistry letters, May-14, Volume: 11, Issue:5	Pharmacophore-Based Virtual Screening for Identification of Negative Modulators of GLI1 as Potential Anticancer Agents.
AID1655601	Antiproliferative activity against human A375 cells transfected with lentivrus-encoding shRNA against GLI1 assessed as reduction in cell viability incubated for 72 hrs by trypan blue or crystal violet staining based assay	2020	ACS medicinal chemistry letters, May-14, Volume: 11, Issue:5	Pharmacophore-Based Virtual Screening for Identification of Negative Modulators of GLI1 as Potential Anticancer Agents.
AID1655596	Inhibition of GLI1 transcriptional activity in human A375 cells assessed as downregulation of GLI1 mRNA expression at 5 uM incubated for 48 hrs by qPCR analysis	2020	ACS medicinal chemistry letters, May-14, Volume: 11, Issue:5	Pharmacophore-Based Virtual Screening for Identification of Negative Modulators of GLI1 as Potential Anticancer Agents.
AID1655603	Antiproliferative activity against human A375 cells transfected with lentivrus-encoding shRNA against GLI2 assessed as reduction in cell viability incubated for 72 hrs by trypan blue or crystal violet staining based assay	2020	ACS medicinal chemistry letters, May-14, Volume: 11, Issue:5	Pharmacophore-Based Virtual Screening for Identification of Negative Modulators of GLI1 as Potential Anticancer Agents.
AID1655594	Inhibition of GLI1 transcriptional activity in HH-responsive mouse NIH3T3 cells assessed as reduction in GLI1 protein expression at 5 uM incubated for 48 hrs in presence of SAG by Western blot analysis	2020	ACS medicinal chemistry letters, May-14, Volume: 11, Issue:5	Pharmacophore-Based Virtual Screening for Identification of Negative Modulators of GLI1 as Potential Anticancer Agents.
AID1655592	Antiproliferative activity against human A375 cells assessed as reduction in cell viability incubated for 72 hrs by trypan blue or crystal violet staining based assay	2020	ACS medicinal chemistry letters, May-14, Volume: 11, Issue:5	Pharmacophore-Based Virtual Screening for Identification of Negative Modulators of GLI1 as Potential Anticancer Agents.
AID1406174	Growth inhibition of mouse Ptch+/- medulloblastoma cells at 2 uM after 72 hrs relative to control	2018	European journal of medicinal chemistry, Aug-05, Volume: 156	Synergistic inhibition of the Hedgehog pathway by newly designed Smo and Gli antagonists bearing the isoflavone scaffold.
AID1406173	Growth inhibition of mouse Ptch+/- medulloblastoma cells at 1 uM after 72 hrs relative to control	2018	European journal of medicinal chemistry, Aug-05, Volume: 156	Synergistic inhibition of the Hedgehog pathway by newly designed Smo and Gli antagonists bearing the isoflavone scaffold.
AID1406171	Growth inhibition of mouse Ptch+/- medulloblastoma cells at 0.25 uM after 72 hrs relative to control	2018	European journal of medicinal chemistry, Aug-05, Volume: 156	Synergistic inhibition of the Hedgehog pathway by newly designed Smo and Gli antagonists bearing the isoflavone scaffold.
AID1406170	Growth inhibition of mouse Ptch+/- medulloblastoma cells at 0.125 uM after 72 hrs relative to control	2018	European journal of medicinal chemistry, Aug-05, Volume: 156	Synergistic inhibition of the Hedgehog pathway by newly designed Smo and Gli antagonists bearing the isoflavone scaffold.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	3 (60.00)	24.3611
2020's	2 (40.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.80

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	12.80 (24.57)
Research Supply Index	1.79 (2.92)
Research Growth Index	4.59 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (12.80)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	5 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
calixarenes Calixarenes: Phenolic metacyclophanes derived from condensation of PHENOLS and ALDEHYDES. The name derives from the vase-like molecular structures. A bracketed [n] indicates the number of aromatic rings.. calixarenes : Originally macrocyclic compounds capable of assuming a basket (or "calix") shaped conformation. They are formed from p-hydrocarbyl phenols and formaldehyde. The term now applies to a variety of derivatives by substitution of the hydrocarbon cyclo{oligo[(1,3-phenylene)methylene]}.. calixarene : A macrocycle composed of 1,3-phenylene groups linked by methylene groups. The number of 1,3-phenylene units in the macrocycle is denoted by the "n" in calix[n]arene name.	2.31	1
mangostin mangostin: xanthone from rind of Garcinia mangostana Linn. fruit. alpha-mangostin : A member of the class of xanthones that is 9H-xanthene substituted by hydroxy group at positions 1, 3 and 6, a methoxy group at position 7, an oxo group at position 9 and prenyl groups at positions 2 and 8. Isolated from the stems of Cratoxylum cochinchinense, it exhibits antioxidant, antimicrobial and antitumour activities.	2.25	1	aromatic ether; phenols; xanthones	antimicrobial agent; antineoplastic agent; antioxidant; plant metabolite
gdc 0449 HhAntag691: inhibits the hedgehog pathway and ABC transporters; has antineoplastic activity	2.17	1	benzamides; monochlorobenzenes; pyridines; sulfone	antineoplastic agent; Hedgehog signaling pathway inhibitor; SMO receptor antagonist; teratogenic agent

Condition	Relationship Strength	Studies
Benign Cerebellar Neoplasms [description not available]	2.17	1
Arachnoidal Cerebellar Sarcoma, Circumscribed [description not available]	2.17	1
Medulloblastoma A malignant neoplasm that may be classified either as a glioma or as a primitive neuroectodermal tumor of childhood (see NEUROECTODERMAL TUMOR, PRIMITIVE). The tumor occurs most frequently in the first decade of life with the most typical location being the cerebellar vermis. Histologic features include a high degree of cellularity, frequent mitotic figures, and a tendency for the cells to organize into sheets or form rosettes. Medulloblastoma have a high propensity to spread throughout the craniospinal intradural axis. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2060-1)	2.17	1
Cancer of Pancreas [description not available]	2.15	1
Pancreatic Neoplasms Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).	2.15	1

chemdatabank.com